Starpharma Holdings Ltd
ASX:SPL

Watchlist Manager
Starpharma Holdings Ltd Logo
Starpharma Holdings Ltd
ASX:SPL
Watchlist
Price: 0.11 AUD -4.35% Market Closed
Updated: May 26, 2024

Starpharma Holdings Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Starpharma Holdings Ltd
Cost of Revenue Peer Comparison

Comparables:
MYX
NEU
BOT
PBP
C
CU6

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Starpharma Holdings Ltd
ASX:SPL
Cost of Revenue
-AU$779k
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cost of Revenue
-AU$99.9m
CAGR 3-Years
26%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Cost of Revenue
-AU$155m
CAGR 3-Years
-28%
CAGR 5-Years
-26%
CAGR 10-Years
-15%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Starpharma Holdings Ltd's Cost of Revenue?
Cost of Revenue
-779k AUD

Based on the financial report for Dec 31, 2023, Starpharma Holdings Ltd's Cost of Revenue amounts to -779k AUD.

What is Starpharma Holdings Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-14%

Over the last year, the Cost of Revenue growth was 68%. The average annual Cost of Revenue growth rates for Starpharma Holdings Ltd have been -14% over the past three years .